The combination of reactivation of p53 along with enhancement of target TLR genes and exposure to appropriate TLR agonists suggests unique immune approaches to the development of anti-cancer drugs and drug combinations based on immune responses via the TLR gene family [14]. Here, TP53 is linked to cancer.